Healthcare Services

Hyperlipidemia Market Growth Forecast With Analysis Of Industry Progress Through 2030

May 29, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Hyperlipidemia Market Change Between 2026 And 2030?

The hyperlipidemia market has experienced consistent expansion in recent years. Projections indicate a rise from $20.92 billion in 2025 to $21.59 billion in 2026, reflecting a compound annual growth rate (CAGR) of 3.2%. This historical expansion is linked to factors such as the increasing incidence of cardiovascular conditions, the extensive adoption of statins, enhanced understanding of cholesterol control, changes in lifestyle including sedentary habits and dietary patterns, and the expanding elderly population.

The hyperlipidemia market is anticipated to show steady expansion in the upcoming years. Its value is expected to climb to $25.54 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.3%. This projected growth can be attributed to several factors, including the increasing uptake of PCSK9 inhibitors, a rise in the diagnosis of familial hyperlipidemia, the broadening of personalized lipid therapies, an escalating demand for preventive cardiology, and improved access to advanced treatments. Significant trends during this forecast period are set to include the wider adoption of combination lipid-lowering therapies, an increased emphasis on early screening and preventive care, the growing utilization of injectable biologics for high-risk patients, the expansion of home-based and long-term lipid management solutions, and a stronger focus on treatment approaches integrated with lifestyle modifications.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12873&type=smp

What Important Drivers Are Powering The Hyperlipidemia Market Growth?

The hyperlipidemia market is projected to grow due to the rising prevalence of chronic conditions like heart disease. Heart diseases encompass conditions that impair the heart’s function. Treatment for hyperlipidemia aids individuals with heart disease by reducing the likelihood of heart attacks, preventing strokes, enhancing endothelial function, and lessening the need for invasive interventions. As an illustration, in April 2025, the Centers for Disease Control and Prevention (CDC), a US-based federal agency, reported that in 2023, approximately 194 million U.S. adults, representing 76.4% of the population, indicated having at least one chronic condition. The reported prevalence was 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the heightened incidence of chronic disorders, such as heart disease, stimulates the expansion of the hyperlipidemia market.

How Are Different Segment Groups Identified Within The Hyperlipidemia Market?

The hyperlipidemia market covered in this report is segmented –

1) By Type: Familial Hyperlipidemia, Acquired Hyperlipidemia

2) By Treatment: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination, Other Treatments

3) By Route of Administration: Oral, Parenteral

4) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegments:

1) By Familial Hyperlipidemia: Familial Hypercholesterolemia (FH), Familial Combined Hyperlipidemia, Familial Dysbetalipoproteinemia

2) By Acquired Hyperlipidemia: Diet-Related Hyperlipidemia, Secondary Hyperlipidemia, Drug-Induced Hyperlipidemia

Which Trends Are Contributing To Changes In The Hyperlipidemia Market?

Major companies in the hyperlipidemia market are concentrating on creating innovative offerings, such as advanced low-density lipoprotein cholesterol-lowering treatments, to secure their presence. For instance, in March 2024, Regeneron Pharmaceuticals, Inc., a US-based biotechnology company, announced that the U.S. Food & Drug Administration (FDA) had approved Praluent (alirocumab) Injection. This marks a significant progression in addressing heterozygous familial hypercholesterolemia (HeFH) in pediatric patients aged 8 and older, providing a targeted method for managing dangerously elevated low-density lipoprotein cholesterol (LDL-C) levels. The recent FDA approval is substantiated by Phase 3 trial results, which showed a 31% reduction in LDL-C levels with consistent dosing. Its well-established safety profile, mirroring that observed in adults, offers reassurance to families and healthcare providers, while its distinction as the first therapy to target the genetically-validated PCSK9 protein represents a milestone in heart disease treatment. Collectively, these attributes position Praluent as a crucial option for the management of high cholesterol in children afflicted with HeFH.

Which Firms Are Competing In The Hyperlipidemia Market?

Major companies operating in the hyperlipidemia market are Pfizer Inc., Johnson and Johnson Limited, Merck and Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Co. Ltd., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Limited, Otsuka Pharmaceutical Co. Ltd., Menarini Group, Dr. Reddy’s Laboratories Ltd., Apotex Inc., Hikma Pharmaceuticals PLC, Cipla Inc., Aspen Pharmacare Holdings Limited, Zydus Lifesciences Ltd.

Access The Complete Hyperlipidemia Market Report:

https://www.thebusinessresearchcompany.com/report/hyperlipidemia-global-market-report

Which Region Is The Primary Market For The Hyperlipidemia Market?

North America was the largest region in the hyperlipidemia market in 2025. The regions covered in the hyperlipidemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Hyperlipidemia Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=12873&type=smp

Browse Through More Reports Similar to the Global Hyperlipidemia Market 2026, By The Business Research Company

Anosmia Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/anosmia-global-market-report

Hyperphosphatemia Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/hyperphosphatemia-treatment-global-market-report

Phospholipid Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/phospholipid-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795